News

The companies will conduct clinical trials to evaluate the combination of Dynavax’s investigational toll-like receptor 9 (TLR9) agonist SD-101, with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) and its investigational

The Israeli company was first to file, making the product eligible for 180 days of market exclusivity. Risedronate sodium tablets, USP are the second approved product indicated to

The agency has granted priority review for this sBLA and is expected to respond by 30 September. The new application is based on data from CheckMate -069, the

As part of the transaction, Actavis will pay Auden £306m in cash and two-year royalty on a percentage of gross profits of one of Auden Mckenzie’s products. Actavis

Around 160 men aged 18 to 64 with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone will be included in the randomized, double-blind, placebo-controlled, parallel

Lenvima is an orally administered molecular targeted agent which inhibits the activities of several different molecules including VEGFR, FGFR, RET, KIT and PDGFR. It particularly inhibits VEGFR, FGFR

This is the first combination of BRAF/MEK inhibitors to demonstrate a statistically significant overall survival benefit for this patient population in two Phase III studies. Results are being

ASP2215 is a receptor tyrosine kinase inhibitor of FLT3 and AXL, which are involved in the growth of cancer cells. ASP2215 demonstrated inhibitory activity against FLT3 internal tandem

Conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis’ collaboration with the US National Cancer Institute (NCI), the Study E1512 is a randomized phase II trial